Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded at B. Riley

Key Points

• B. Riley has initiated coverage of Corbus Pharmaceuticals with a "buy" rating and a price target of $28.00, suggesting a potential upside of 187.18% from its current stock price.
• The company's stock has experienced a remarkable 342% year-to-date surge and has an average analyst rating of "Moderate Buy" with an average target price of $49.38.
• Despite strong interest from institutional investors who own 64.64% of the stock, Corbus reported a quarterly earnings miss with an EPS of ($1.39), falling short of the consensus estimate.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) was upgraded by equities researchers at B. Riley to a "strong-buy" rating in a research report issued on Wednesday, July 30th, Marketbeat.com reports. The firm presently has a $28.00 price target on the biopharmaceutical company's stock. B. Riley's target price suggests a potential upside of 207.35% from the stock's current price. B. Riley also issued estimates for Corbus Pharmaceuticals' Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.63) EPS, Q4 2025 earnings at ($1.63) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($5.49) EPS and FY2027 earnings at ($5.50) EPS.

CRBP has been the topic of a number of other research reports. Lifesci Capital raised shares of Corbus Pharmaceuticals to a "strong-buy" rating in a report on Saturday, July 12th. HC Wainwright decreased their price target on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Oppenheimer cut their price objective on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Royal Bank Of Canada decreased their target price on shares of Corbus Pharmaceuticals from $65.00 to $58.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Corbus Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $49.00.

Corbus Pharmaceuticals Stock Up 2.4%

CRBP traded up $0.21 during trading on Wednesday, reaching $9.11. 93,283 shares of the company were exchanged, compared to its average volume of 127,605. The company has a market cap of $111.48 million, a price-to-earnings ratio of -1.91 and a beta of 3.20. Corbus Pharmaceuticals has a 12-month low of $4.64 and a 12-month high of $61.89. The company's 50-day moving average is $8.39 and its two-hundred day moving average is $7.77.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.13). Equities analysts forecast that Corbus Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN raised its holdings in shares of Corbus Pharmaceuticals by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company's stock valued at $76,000 after acquiring an additional 2,195 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Corbus Pharmaceuticals by 46.8% in the 4th quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock worth $97,000 after purchasing an additional 2,616 shares during the period. Aquatic Capital Management LLC bought a new stake in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $101,000. Two Sigma Advisers LP purchased a new position in shares of Corbus Pharmaceuticals during the fourth quarter valued at about $130,000. Finally, Corton Capital Inc. bought a new position in Corbus Pharmaceuticals in the second quarter worth about $86,000. Hedge funds and other institutional investors own 64.64% of the company's stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.